**MAPS in the Media**

**The New York Times**

Molly at the Marriott: Inside America’s Premier Psychedelics Conference by Casey Schwartz
May 6, 2017 - *The New York Times* reviews Psychedelic Science 2017, a six-day international gathering hosted by MAPS and The Beckley Foundation. *The New York Times* speaks with MAPS Founder Rick Doblin, Ph.D., and MAPS Policy and Advocacy Manager Natalie Lyla Ginsberg to discuss the success and cultural impact of the conference. “We are not the counterculture,” explains Doblin, “we are the culture.”

**EAST BAY EXPRESS**

World’s Largest Psychedelic Drug Conference “Psychedelic Science 2017” by Blake Gillespie
April 19, 2017 - *East Bay Express* reports that in 2017, psychedelics are undergoing concurrent waves of cultural renaissances. One only has to look at the potpourri of workshops by researchers and specialists worldwide that will descend on the Psychedelic Science 2017 conference: MDMA-assisted psychotherapy is the front-runner in medicalization, the family tree includes issues such as ayahuasca retreats, ketamine-assisted psychotherapy, psychedelic harm reduction at festivals, holotropic breathing, and LSD microdosing.

**CBS SF Bay Area**

Psychedelic Drug Banned In The U.S. May Help Battle Addiction by Susie Steimle
May 15, 2017 - *CBS San Francisco Bay Area* explores new research into the therapeutic benefits of psychedelics like ibogaine and MDMA for treating addiction and PTSD. Susie Steimle of CBS speaks with MAPS Founder Rick Doblin, Ph.D., and psychedelic researchers and study participants about ongoing research with ibogaine and MDMA combined with therapy as a potential treatment for a variety of mental health issues. “It just gives you a view into yourself that I had just never had before,” explains Andy Gold, MDMA-assisted psychotherapy study participant from a MAPS-sponsored clinical trial.

**PLAYBOY**

MDMA’s Long, Strange Trip from Club Drug to Military Medicine by Seven McDonald
May 17, 2017 - *Playboy* features MDMA research conducted by MAPS. Underground MDMA-assisted psychotherapy patient Seven McDonald of *Playboy* speaks to MAPS Founder Rick Doblin, Ph.D., MAPS-sponsored researchers Michael Mittofer, M.D., and Annie Mittofer, B.S.N., and study participant CJ Hardin about current clinical trials of MDMA-assisted psychotherapy for PTSD. “People ask all the time if this is a cure,” explains Michael Mittofer. “I think a better term is maybe durable remission, because we don’t know. People can make so much progress and be free of symptoms that were debilitating before, yet if they get a strong enough trigger, it can happen that the symptoms come back.”

**YouGov**

Majority of Americans Ready to Embrace Psychedelic Therapy by Gregory McCarriston
June 23, 2017
YouGov explores the therapeutic potential of psychedelics as treatments for depression, anxiety, and PTSD, providing new data providing new data collected by YouGov that, “shows that many Americans are ready to embrace psychedelic therapies.” Gregory McCarriston of YouGov explains that, “While more than half of all Americans may support research into psychedelics for therapeutic use, a 63% majority also said they would personally be open to medical treatment with psilocybin, ketamine, or MDMA if faced with a pertinent medical condition—assuming the substance is proven safe.”

Example questions from this nationally representative survey of 1,100+ U.S. adults (demographic breakdowns available at today.yougov.com)

Q: In general, do you support or oppose researchers being allowed to study illegal psychedelic substances (e.g., mushrooms, MDMA, ketamine, etc.) in medical trials to investigate their potential medicinal benefits, despite their illegal status?
53% Support
21% Oppose
27% Don’t know

Q: Please imagine that MDMA was approved as a prescription drug...If available to you, would you or would you not try this treatment if you were faced with a similar medical condition?
56% Would
21% Would not
22% Don’t know
Psychedelics: Medicine or Madness?
by Moshe Kasher

Could A Club Drug Be The Secret To Curing PTSD?
by Louisa Kamps
March 1, 2017 - Elle Magazine speaks to MDMA-assisted psychotherapy study participant Julie Nelson about her experience overcoming PTSD through a MAPS-sponsored clinical trial. Louisa Kamps of Elle also interviews MAPS-sponsored MDMA researchers Marcela Ot’alora, M.A., L.P.C., and Annie Mithoefer, B.S.N., about their personal experiences providing psychedelic therapy to help participants process trauma. “Researchers working on the new MDMA trials think that the drug provides relief by helping people deal directly with the emotional fallout of their trauma,” says Kamps. “We think MDMA removes obstacles and catalyzes recovery by helping people start to access their own healing capacity,” explains Mithoefer. “Rather than trying to avoid triggers, they’re able look at them in a different light, communicate about them, and begin to let them go.”

MDMA and LSD May Soon Be Used to Treat Mental Disturbances
by Marcelo Leite
June 17, 2017 - Brazil’s largest newspaper, Folha de S. Paulo, covers MAPS’ MDMA-assisted psychotherapy for PTSD studies, highlighting research results presented at the recent Psychedelic Science 2017 conference. “After six days of presented works, the moment had come to commemorate the end of the 2017 Psychedelic Science Conference, which had united more than 3,000 people from 40 countries in Oakland, California, at the end of April. The mood was one of euphoria over the possibility of rehabilitating various drugs of dubious reputation,” says Marcelo Leite of Folha de S. Paulo.

Can Psychedelics Be Therapy? Allow Research to Find Out
by Aaron E. Carroll
July 17, 2017 - The New York Times explores psychedelic therapy as a potential treatment for PTSD, depression, addiction, and anxiety associated with life-threatening illness. Aaron Carroll of The New York Times reports on LSD, psilocybin, and MDMA research, highlighting MAPS’ clinical trials of MDMA-assisted psychotherapy for PTSD and LSD-assisted psychotherapy for anxiety associated with life-threatening illness. “With the potential to help curb more serious addictions and ease the symptoms of mental illnesses, it seems odd to continue to make it nearly impossible to research the therapeutic potential of psychedelics,” explains Carroll.